Levetiracetam Tablet, Film Coated, Extended Release
Product Images NDC 63629-9847

Product Visual Gallery

This gallery contains 8 technical images submitted to the FDA as part of the official labeling for Levetiracetam (NDC 63629-9847). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.

As provided by Bryant Ranch Prepack, these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.

FDA Label Image

Clcr 2 (13)

A formula for estimating creatinine clearance (CLcr) is displayed. It calculates CLcr using age in years, weight in kilograms, serum creatinine in mg/dL, and includes a multiplier of 0.85 for female patients. The formula components are arranged as a fraction.*

FDA Label Image

Clcr 2 (2)

A text panel showing a formula for adjusting creatinine clearance (CLcr) based on body surface area (BSA), with the formula CLcr (mL/min/1.73m²) = (CLcr (mL/min) ÷ BSA subject (m²)) × 1.73.*

FDA Label Image

Levetiracretam Structural Formula (3)

Chemical structure of levetiracetam showing its molecular arrangement including a pyrrolidone ring and a side chain with an ethyl group.*

FDA Label Image

Figure 1 (4)

A bar chart compares the percentage of patients across three groups: Placebo (7.4%), Immediate-release levetiracetam tablets 1000 mg/day (37.1%), and Immediate-release levetiracetam tablets 3000 mg/day (39.6%). Statistically significant differences versus placebo are marked with an asterisk for both levetiracetam groups. The y-axis represents the percentage of patients, ranging from 0% to 45%.*

FDA Label Image

Figure 2 (5)

A bar chart showing the percentage of patients across three groups: Placebo (6.3%, N=111), Immediate-release levetiracetam tablets 1000 mg/day (20.8%, N=106), and Immediate-release levetiracetam tablets 2000 mg/day (35.2%, N=105). The chart indicates statistical significance versus placebo for the levetiracetam groups.*

FDA Label Image

Figure 3 (6)

A bar chart displaying the percentage of patients for placebo and immediate-release levetiracetam 3000 mg/day groups. The placebo group (N=104) shows 14.4% of patients, while the levetiracetam group (N=180) shows 39.4%, with a statistical significance note indicating the latter is significantly higher than placebo.*

FDA Label Image

Figure 4 (7)

A bar graph comparing the percentage of patients between two groups: 19.6% for the placebo group (N=97) and 44.6% for the immediate-release levetiracetam tablets group (N=101). The graph includes a notation indicating statistical significance versus placebo. The y-axis represents the percentage of patients.*

FDA Label Image

Label (Lbl636299847)

Label for Levetiracetam Extended-Release Tablets, USP 500 mg by Bryant Ranch Prepack. The label shows the NDC 63629-9847-1, with a package size of 21 tablets. It includes storage instructions and manufacturer detail, Zhejiang Huahai Pharma Co., Ltd., and a barcode on the right side.*

* About these descriptions: Image descriptions on this page are generated by automated AI analysis of the product label images from the manufacturer's FDA label submission (SPL). They are provided for reference only and may contain errors or omissions. Always rely on the printed label itself and the official FDA labeling, and consult a pharmacist or healthcare professional with any questions about this product.